IT Will Be Cornerstone In Personalizing Medicine, Siemens Says
This article was originally published in The Gray Sheet
Executive Summary
Siemens has established itself as a leader in both imaging and in vitro diagnostics with the aid of recent multibillion-dollar acquisitions, but the company's ability to leverage its IT expertise will be critical to tie the pieces together, the firm says
You may also be interested in...
Siemens Claims Top IVD Slot With $7 Billion Dade Behring Purchase
Siemens' medical unit solidified its status July 25 as the only company offering a comprehensive suite of both imaging and in vitro diagnostic products with its $7 billion acquisition of Dade Behring
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.